
    
      Evaluation on the long-term safety and tolerability, including local tolerability of the
      implant site, of the 84-mg octreotide hydrogel implant in subjects with acromegaly who had
      been successfully treated with the 84-mg octreotide hydrogel implant in the Phase III study
      IP107-001.
    
  